Clinical Trial Detail

NCT ID NCT02879617
Title A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Liza Villaruz, MD
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Age Groups: adult senior

Additional content available in CKB BOOST